AVE 8488Alternative Names: AVE8488
Latest Information Update: 18 Mar 2009
At a glance
- Originator sanofi-aventis
- Class Sleep disorder therapies
- Mechanism of Action Serotonin 2A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 31 Aug 2005 Preclinical trials in Sleep disorders in France (unspecified route)